Key Highlights
- Neuronetics shares were trading up 17.70% at $2.66, against a prior close of $2.26.
- Third-quarter Revenue rose 12.5% to about $42.0 million.
- Gross Margin expanded to 52.2% from 45.9%.
- Income from operations was $0.5 million, against a $7.3 million loss a year ago.
- Full-year revenue guidance of $160 million to $164 million was unchanged.
Profitability Turns the Corner
Neuronetics (NASDAQ:STIM) shares were trading up 17.70% at $2.66 on Wednesday after third-quarter results showed a turn toward profitability. Revenue rose 12.5% to about $42.0 million, gross margin expanded to 52.2% from 45.9%, and operating expenses fell 12.6% to $21.3 million. Income from operations was $0.5 million against a $7.3 million loss a year earlier.
Adjusted EBITDA was $1.9 million, against a loss of $4.7 million, and the net loss narrowed to $1.7 million, or $0.02 per share.
Clinics and Devices Both Contribute
Greenbrook clinic revenue rose 20.1% to $26.2 million, helped by revenue cycle gains and double-digit growth in Spravato. NeuroStar revenue rose 1.8% to $15.8 million on a record quarter of system sales, partly offset by lower session revenue. More than half of units sold were Capital or Lease deals, which helped margins.
Guidance and Catalysts
Revenue guidance of $160 million to $164 million is unchanged, gross margin guidance was narrowed to 49% to 50%, and Operating Expense guidance was lowered to $92.5 million to $95.5 million. A 510(k) for an accelerated TMS protocol was submitted in August. The company is preparing for the launch of Compass Pathways’ COMP-360 in treatment-resistant depression, with launch expected in the first half of 2027.
Penny Stock Risks Remain
The 52-week range runs from $0.80 to $3.44, so the stock has more than tripled from its low. The company still expects limited net cash use in the second half, and a stock at this price level can move sharply on small changes in sentiment.






Please wait processing your request...